Neurotensin may be new blood biomarker of biliary atresia
Levels of neurotensin, a small protein highly present in the gastrointestinal tract, are higher than normal in the blood and liver of biliary atresia…
News
Imdusiran plus immunotherapy may help in chronic hepatitis B
In ongoing proof-of-concept Phase 2a trials, Arbutus BioPharma’s imdusiran is showing an ability to possibly eliminate chronic hepatitis B infections when used in…
Abuse suspected for skin bruising in case of PFIC2 liver disease
An 8-month-old girl with type 2 progressive familial intrahepatic cholestasis (PFIC2) who was seen at a hospital emergency department with extensive skin bruising was suspected…
Blood levels of GDF15 protein may help in liver cancer risk of MASLD
High blood levels of the growth differentiation factor 15 (GDF15) protein are associated with an elevated risk of liver cancer and other liver-related complications among…
Livmarli sustains benefit for Alagille patients over 7 years: Trial data
Nearly all children with Alagille syndrome who received Mirum Pharmaceuticals’ Livmarli (maralixibat) for seven years as part of clinical studies continued to experience…
BJT-778 antibody therapy shows early promise in Hep D trial
Bluejay Therapeutics’ investigational antibody therapy BJT-778 appears to safely and effectively lower levels of the hepatitis D virus (HDV) and markers of liver inflammation…
Global Fatty Liver Day to raise awareness of ‘concealed epidemic’
Global Fatty Liver Day, this year falling on June 13, is an annual effort to raise awareness about metabolic dysfunction-associated steatotic liver disease…
Seladelpar still eases itch, liver damage after 2 years: PBC trial
Two years of treatment with seladelpar, Gilead Sciences’ oral candidate, safely results in rapid and sustained reductions in itching and liver damage markers for…
Intrahepatic cholestasis of pregnancy risks mothers, newborns
Pregnant women with intrahepatic cholestasis of pregnancy (ICP) have an increased risk of other pregnancy-related problems, including gestational diabetes and preeclampsia, or sudden high…
Elafibranor, now Iqirvo, wins FDA accelerated approval for PBC
The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Ipsen’s elafibranor as a second-line treatment for primary biliary cholangitis (PBC).
Recent Posts
- Awareness month focuses on challenges for rural communities
- My son’s fourth birthday is yet another milestone to celebrate
- Weight loss surgery may protect liver with MASH-related cirrhosis
- Livmarli relieves itch in adolescents with Alagille syndrome: Analysis
- HBV vaccine birth dose not tied to premature babies’ lung disease risk